We will encapsulate our opinion in short here. This is potentially every investors opportunity of being in on what normally we only hear about "after the fact" when the best and biggest investment opportunities have already climbed out of our reach. Major pharmaceuticals are not looking at this just because they have nothing better to do. We are sure they see this as a huge revenue source and the rest of the equation of what they may do we will leave to your sensible conclusions of what can happen. We will close with this posting by posting what the Acting Chairman of the Board of Cardiogenics has already accomplished and you will understand, but Cardiogenics is even more valuable.
J. Neil Tabatznik
Acting Chairman of the Board
Cardiogenics Holdings Inc
Mississauga , ON
Sector: HEALTHCARE / Diagnostic Substances
59 Years Old
Mr. Tabatznik is the Chairman, CEO of Arrow Pharmaceuticals Inc. Arrow Pharmaceuticals is part of a global generic drug company established in 2000, and has seen rapid growth from $0 to $700 million in 8 years. The Arrow Group has sales operations in 5 continents and employs more than 1000 people worldwide. Prior to Arrow Pharmaceuticals, Mr. Tabatznik was the Chairman, CEO of Genpharm Inc. (1993-2000), which was acquired by MerckKGaA in 1994 and is now a part of Mylan Inc. the world's third largest generic and specialty pharmaceutical company. He was a Barrister-at-Law in London and was called to the Bar of England and Wales in 1978. He has extensive expertise in pharmaceutical manufacturing and negotiations of agreements with multinational companies.
Watson to Acquire Arrow Group
-- Arrow Will Expand Watson's Global Commercial Footprint -- Transaction Expected to be Accretive to Cash Earnings Per Share in 2010 Before Synergies -- Enhances Watson's Long Term Growth Profile
MORRISTOWN, N.J., June 17, 2009 /PRNewswire-FirstCall via COMTEX/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has entered into a definitive agreement to acquire privately held Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in a global pharmaceutical company with over $3 billion in revenue, commercial operations in over 20 countries, and a robust product portfolio and pipeline. Watson expects the transaction to close in the second half of 2009, and be accretive to cash earnings per share in 2010 before synergies.
Arrow is one of the fastest growing generic pharmaceutical companies in the world, generating $647 million in revenues in 2008, representing a 67% organic compound annual growth rate since 2001. Arrow markets more than 100 molecules in over 20 different countries, including key markets such as Canada, France and the U.K. In addition, Arrow has an extensive pipeline that will be launched across multiple markets, including significant potential U.S. launches in each of the next three years. Arrow has approximately 1,000 employees worldwide, including more than 250 in R&D.
